Q3 results were below our expectations, but the main reason for the disappointment was negative FX effects. However, our forecasts for the next few years have been lowered slightly as the company's cost structure has slightly ballooned, but we believe that the increased potential from the Thirona Retina acquisition more than offsets this.

Revenio's subsidiary Icare yesterday announced the launch of the iCare ST500 packing the essential features of iCare rebound tonometry technology into a modern slit lamp-based design.

evenio announced yesterday that it has signed an agreement to acquire the Dutch software company Thirona Retina. Revenio previously used Thirona's AI solution as part of its ILLUME screening solution, and Revenio is a minority shareholder in Thirona, so the takeover target is familiar to the company.

Revenio's revenue growth accelerated faster than we anticipated, and the Q2 operating result exceeded our expectations. The company has returned to profit growth as expected, and future growth drivers are developing promisingly, laying the foundation for profitable growth in the medium term as well.